FOXA vs STOK · P/E 14, rev $17.13B vs rev $15.6M
Fox Corp Class A (FOXA) versus Stoke Therapeutics Inc (STOK) — a side-by-side from cached financials, not a winner call.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
Stoke Therapeutics Inc (STOK) is a biotechnology company listed on NASDAQ.
Latest reported FOXA revenue for 2026-06-30 was $17.13B. Net income was $1.73B. Revenue was up 5.1% from 2025-06-30 to 2026-06-30. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
Latest reported STOK revenue for 2026-06-30 was $15.6M. Net income was -$111.6M. STOK currently screens at market cap $1.88B.
FOXA currently screens at market cap $24.50B and trailing P/E 14.1. STOK currently screens at market cap $1.88B.
Not investment advice. Open the FOXA and STOK stock pages for the full models.
Not investment advice.